Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Men Treated With Second-Line Chemotherapy

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

(2013) C. Parker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401

(2012) William Kevin Kelly et al.   JOURNAL OF CLINICAL ONCOLOGY

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

(2012) Howard I. Scher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

(2012) Charles J. Ryan et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Perturbation Method for Inference on Regularized Regression Estimates

(2011) Jessica Minnier et al.   JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

(2011) Karim Fizazi et al.   LANCET

Abiraterone and Increased Survival in Metastatic Prostate Cancer

(2011) Johann S. de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

(2010) Johann Sebastian de Bono et al.   LANCET

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Importance of Identifying and Validating Prognostic Factors in Oncology

(2010) Susan Halabi et al.   SEMINARS IN ONCOLOGY

Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer

(2009) A. J. Armstrong et al.   CLINICAL CANCER RESEARCH

Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial

(2009) Cora N. Sternberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Imputing missing covariate values for the Cox model

(2009) Ian R. White et al.   STATISTICS IN MEDICINE

Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer

(2008) J. S. de Bono et al.   CLINICAL CANCER RESEARCH